Previous 10 | Next 10 |
2023-10-26 01:30:02 ET Summary 89bio shows promise in NASH therapeutics, backed by robust Phase 2b trials of its drug pegozafermin. Financially stable with a significant cash runway, but a sharp YoY increase in operating expenses without a partnership to offset some costs is a con...
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Mana...
2023-10-10 16:13:47 ET Shares of 89bio (NASDAQ: ETNB) closed Tuesday's trading session down by more than 37%. The healthcare company didn't release any news, but its peer, Akero Therapeutics , released disappointing trial data for a nonalcoholic steatohepatitis (NASH) therap...
2023-10-10 15:58:09 ET More on Akero Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data Akero Therapeutics: An Assessment Biggest stock movers today: Coherent, Truist Financial, Akero Therapeutics and more Akero plummets after m...
2023-10-10 13:28:32 ET Summary Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Despite the setback, AKRO stock is still trading higher than it was in September 2022, before another Phase 2 study succeeded...
2023-10-10 13:10:42 ET More on 5E Advanced Materials 5E Advanced Materials, Inc. (FEAM) Q4 2023 Earnings Call Transcript 5E Advanced Materials hires new contractors to complete small scale boron facility Seeking Alpha’s Quant Rating on 5E Advanced Materials ...
2023-10-10 10:00:01 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further deta...
2023-10-10 08:23:35 ET More on Longeveron Longeveron: Alzheimer's Phase 2 Data Around The Corner Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript Longeveron falls after mid-stage data for Alzheimer’s candidate Longeveron announces pricing for ri...
2023-10-10 07:35:13 ET More on Akero Akero Therapeutics: An Assessment Biggest stock movers today: Hyatt Hotels, PagerDuty and more Cantor starts Akero at buy, bullish on upcoming data for NASH drug Seeking Alpha’s Quant Rating on Akero Therapeutics ...
2023-09-21 08:53:15 ET More on 89bio Seeking Alpha’s Quant Rating on 89bio Historical earnings data for 89bio Financial information for 89bio 89bio, Inc.: A Big Bet On NASH 89bio gains as UBS starts at Buy; cites upcoming data from Akero ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...